Tirzepatide in the UK: regulatory status

In the UK, tirzepatide is a licensed prescription-only medicine sold under the brand name Mounjaro. The MHRA granted its first UK marketing authorisation in 2023 for type-2 diabetes, followed later that same year by a second authorisation for weight management.^[1] This article covers what each authorisation permits, what NICE has decided about NHS access, which safety signals have appeared since the drug entered routine UK use, and what has not changed in the past 12 months. Import rules for UK residents considering sourcing Mounjaro from abroad are addressed separately in the companion article on tirzepatide UK import rules.

The MHRA marketing authorisations

Mounjaro entered UK regulatory approvals via a Great Britain (GB) marketing authorisation granted by the MHRA, following the EMA central authorisation for the EU and EEA, which was granted on 15 September 2022.^[2] The MHRA authorised Mounjaro for type-2 diabetes first, with the weight-management authorisation following on 8 November 2023.^[1] Both authorisations are held by Eli Lilly Nederland B.V. The drug's pharmacology and mechanism of action as a dual GIP and GLP-1 receptor agonist are covered in depth on the tirzepatide peptide page.

The type-2 diabetes authorisation covers adults with insufficiently controlled type-2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy when metformin is inappropriate, or in combination with other antidiabetic medicines. The dose range in both indications is 2.5 mg to 15 mg by weekly subcutaneous injection, starting at 2.5 mg and titrated in 4-week intervals based on tolerability and clinical response.

The weight-management authorisation covers adults with an initial BMI of 30 kg/m2 or above (obesity), or 27 to 29.9 kg/m2 (overweight) when at least one weight-related comorbidity is present, such as prediabetes, hypertension, hyperlipidaemia, or cardiovascular disease.^[1] In both cases, tirzepatide must be combined with a reduced-calorie diet and increased physical activity. A four-dose KwikPen presentation was separately approved by the MHRA in January 2024, in addition to the original single-dose autoinjector.

The MHRA authorisation for the UK sits separately from the EMA central procedure. This matters post-Brexit: EU and GB licences are distinct instruments. Mounjaro is not authorised for use in Northern Ireland through the MHRA GB process; Northern Ireland continues to follow the EMA centrally authorised route. For the cross-country comparison, see tirzepatide regulatory status by country. For context on how the UK regulatory framework compares to others we track, see the UK regulation hub.

NICE technology appraisals: the NHS access gateway

Holding an MHRA marketing authorisation means Mounjaro can legally be prescribed in the UK. It does not mean the NHS will fund it. NHS funding decisions in England run through the National Institute for Health and Care Excellence (NICE), which issued two separate technology appraisals covering tirzepatide. Readers comparing the NICE process with how other EU member states handle access should see the parallel article on tirzepatide regulatory status in Sweden, where TLV makes equivalent subsidy decisions.

NICE TA924, published 25 October 2023, recommended tirzepatide as a treatment option for type-2 diabetes in adults who have not achieved adequate glycaemic control on triple oral therapy, and where insulin therapy raises clinical concerns or is not acceptable.^[3] The evidence cited includes primarily the SURPASS programme, particularly SURPASS-2 (a head-to-head against semaglutide 1 mg at the same weekly dose). Eligible patients typically have an HbA1c at or above 58 mmol/mol (7.5%) and have already tried metformin plus at least two other antidiabetic drug classes. Prescribing continues as long as glycaemic targets are met.

NICE TA1026, published 23 December 2024, recommended tirzepatide for managing overweight and obesity within specialist NHS weight-management services, alongside a reduced-calorie diet and increased physical activity.^[4] The access criteria are more restrictive than the marketing authorisation itself: BMI of 35 or above plus at least one weight-related comorbidity, or BMI between 30 and 34.9 with comorbidities meeting defined severity thresholds. Access is phased into specialist services rather than open GP prescribing, and integrated care boards have introduced waiting lists in some areas because of service capacity constraints.

The two TAs do not overlap. A patient with type-2 diabetes and obesity could meet TA924 criteria but not TA1026 criteria if their BMI and comorbidity profile do not satisfy the obesity-management thresholds. The clinical settings also differ: a diabetes clinic for TA924, a specialist weight-management service for TA1026. Eligibility under one TA does not transfer to the other.

Private prescription remains an option for patients outside NHS criteria. In 2026 private pricing for Mounjaro in the UK runs approximately £180 to £400 per month depending on dose strength and pharmacy. NHS Scotland, Wales, and Northern Ireland set their own guidance separately from NICE England technology appraisals, and access criteria can vary across the four nations.

What is not in the UK authorisation

Two omissions are worth naming directly, because both appear in press coverage alongside the UK Mounjaro story.

First, the Zepbound brand does not exist in the UK. Zepbound is an FDA-approved presentation of tirzepatide for chronic weight management and obstructive sleep apnea, sold in the US under a separate brand from Mounjaro. The EMA and the MHRA took a different approach: they authorised both the diabetes and weight-management indications under the single Mounjaro brand. A UK patient or prescriber searching for 'Zepbound' will not find a licensed UK product. Mounjaro is the only authorised tirzepatide brand in the UK.^[1]

Second, there is no MHRA authorisation for tirzepatide specifically in obstructive sleep apnea in the UK as of writing. The FDA approved Zepbound for this indication in December 2024 based on the SURMOUNT-OSA trial results. That indication has not been the subject of an MHRA application or a NICE technology appraisal in the UK. The article on the UK regulation hub tracks new indications as they develop.

Post-authorisation safety monitoring

Two MHRA safety communications since authorisation are relevant to UK prescribers and patients of Mounjaro. Both appeared in the period covered by this article's review window.

In June 2025, the MHRA issued guidance on oral contraceptive interactions with GLP-1 receptor agonists including Mounjaro. Tirzepatide can reduce the absorption of oral contraceptives, particularly in people who are overweight or obese.^[5] The recommendation is to use a non-oral contraceptive method, or to add a barrier method, for four weeks after starting tirzepatide and after each dose escalation. The same guidance applies to semaglutide and other GLP-1 class medicines.

In February 2026 the MHRA Safety Roundup flagged two separate Mounjaro issues. The first: GLP-1 receptor agonists as a class carry rare reports of necrotising and fatal pancreatitis, and healthcare professionals should remain alert to symptoms.^[6] The second: a falsified batch of Mounjaro KwikPen 15 mg (batch D873576) was identified at one UK online pharmacy. Pens in the falsified batch had a faulty dose mechanism. The MHRA asked prescribers and patients to stop use and report suspected reactions via the Yellow Card scheme.

The EMA has a set of ongoing post-authorisation studies for Mounjaro covering: long-term cardiovascular outcomes, medullary thyroid carcinoma risk (an observed signal in rodent studies), real-world safety data collection, and the obstructive sleep apnea indication. The product information was last updated at revision 20 on 26 February 2026, incorporating data from the SUMMIT trial in heart failure with preserved ejection fraction.^[2] The CHMP declined to approve a separate HFpEF indication but agreed the data should appear in the label.

The label carries a warning about thyroid C-cell tumours observed in rodent studies. Medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 are contraindications in the UK authorisation, consistent with the broader incretin class.

What changed in the 12 months to July 2026

The core UK regulatory position for tirzepatide has not changed in the past 12 months. Both MHRA marketing authorisations remain in effect. NICE TA924 and TA1026 continue to govern NHS access on the same criteria.

Three developments are worth noting. The first is the CHMP positive opinion in December 2025 to extend Mounjaro to adolescents and children aged 10 and over with type-2 diabetes.^[7] This is an EMA procedure and, once formalised by the European Commission, will reflect the EU position. The MHRA may review its own label on a similar basis, but UK and EU licences are separate instruments post-Brexit and any UK label update would require a distinct MHRA step.

The second is the counterfeit warning issued in February 2026, addressed above. Counterfeit Mounjaro is a live MHRA concern, not a hypothetical. The growth of the grey market for weight-loss medicines in the UK, driven by NHS access constraints and the waiting-list problem under TA1026, has created a supply chain outside the licensed route.^[6] The risks of sourcing tirzepatide outside the authorised pharmacy route, including counterfeit product exposure, are covered in the companion piece on tirzepatide UK import rules.

The third is the continued gap between the marketing authorisation scope and NHS eligibility. Mounjaro can be legally prescribed off-label by a UK clinician for any patient they consider appropriate, at their clinical responsibility. But the NHS funding route through TA924 and TA1026 is the main access mechanism for most patients, and the population excluded by those criteria, including people with BMI between 30 and 34.9 and less severe comorbidities, must either access tirzepatide privately or wait.

Where this leaves patients today

If you have type-2 diabetes and are not at target on triple oral therapy, you may be eligible under NICE TA924. Talk to your diabetes team; the GP or hospital specialist will assess your HbA1c, your existing treatment history, and whether insulin is clinically appropriate. If you are eligible, Mounjaro can be prescribed on the NHS. The clinical evidence base for tirzepatide in type-2 diabetes is summarised on the tirzepatide peptide page.

If your main concern is weight management, eligibility under TA1026 depends on both BMI and comorbidity severity, and on access to a specialist weight-management service. Local capacity varies. If you do not meet the criteria or cannot access an NHS service within a reasonable time, private prescription is the current alternative, with the costs and counterfeit risks that entails. This is not medical advice; the right conversation is with a clinician who knows your situation.

For the cross-country picture on tirzepatide regulation, see tirzepatide regulation by country and the UK regulation hub.